Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × chiauranib × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4 Gynecologic 3 Lymphoid 2 Sarcoma 1 Other solid neoplasm 1 Gastrointestinal 1 Breast 1

Conditions

Interventions

Doxorubicin 40 Imatinib Mesylate 30 Cyclophosphamide 20 Sunitinib 19 pembrolizumab 17 Gemcitabine 17 Temozolomide 16 Irinotecan 13 Bevacizumab 12 pazopanib 11 nilotinib 11 Trabectedin 11 ripretinib 10 fludarabine 9 Docetaxel 9 Carboplatin 9 olaratumab 8 eribulin 8 Ibandronic Acid 8 avapritinib 7 anlotinib 7 Radiation 7 Paclitaxel 7 Ifosfamide 7 spartalizumab 6 regorafenib 6 Vincristine 6 Fluorouracil 6 Dacarbazine 6 Cisplatin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05497843 2025-04-03

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Chipscreen Biosciences, Ltd.

Phase 2 Completed

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡